Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company’s nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings. Proactive: We're excited to have our first interview with you. I know you recently took over as CEO, so first off, congratulations on the role. Can you give us a little background on yo ...